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Abstract: Liver cancer is the fourth leading cause of cancer-related death globally, accounting for
approximately 800,000 deaths annually. Hepatocellular carcinoma (HCC) is the most common
type of liver cancer, comprising approximately 80% of cases. Murine models of HCC, such as
chemically-induced models, xenograft models, and genetically engineered mouse (GEM) models,
are valuable tools to reproduce human HCC biopathology and biochemistry. These models
can be used to identify potential biomarkers, evaluate potential novel therapeutic drugs in
pre-clinical trials, and develop molecular target therapies. Considering molecular target therapies,
a novel approach has been developed to create genetically engineered murine models for HCC,
employing hydrodynamics-based transfection (HT). The HT method, coupled with the Sleeping
Beauty transposon system or the CRISPR/Cas9 genome editing tool, has been used to rapidly and
cost-effectively produce a variety of HCC models containing diverse oncogenes or inactivated tumor
suppressor genes. The versatility of these models is expected to broaden our knowledge of the
genetic mechanisms underlying human hepatocarcinogenesis, allowing the study of premalignant
and malignant liver lesions and the evaluation of new therapeutic strategies. Here, we review recent
advances in GEM models of HCC with an emphasis on new technologies.
Keywords: hepatocellular carcinoma; genetically engineered mouse; hydrodynamics-based
transfection; sleeping beauty transposon; CRISPR/Cas9
1. Introduction
Liver cancer is a major health concern worldwide; it is the second leading cause of cancer-related
deaths in East Asia and sub-Saharan Africa and the sixth in Western countries [1,2]. The main risk
factors for liver cancer are well known and include hepatitis B virus (HBV) infection, hepatitis C virus
(HCV) infection, alcohol intake, liver cirrhosis, metabolic syndrome, or a combination of the above [3].
Hepatocellular carcinoma (HCC) develops through a series of genetic and epigenetic changes in
proto-oncogenes and tumor suppressor genes in the liver environment, wherein hepatic fibrosis or
cirrhosis occurs after sustained liver damage [4].
Therapeutic options for patients with chronic liver disease and cirrhosis exist, such as potent
antiviral therapies for hepatitis B and C, alcohol abstinence programs, and exercise routines for
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metabolic syndrome. However, HCC patients who are diagnosed at an advanced stage have limited
medical options; moreover, these may only increase the mean overall survival by a few months [5].
Furthermore, the process of anti-HCC drug discovery has been difficult and inefficient, as reflected
by the high attrition rate of drugs that enter preclinical testing but fail to attain FDA (Food and
Drug Administration) approval [6]. Therefore, understanding the molecular signaling pathways or
protein–protein interactions that play crucial roles in hepatocarcinogenesis should provide important
information for the treatment of HCC.
The mouse (Mus musculus) is considered the best animal model for cancer research due to its
physiological and molecular similarities with human biology, in addition to its advantages in terms
of size, reproductive capacity, and lifespan. Mouse models for HCC have been developed through
the introduction of genetic changes that contribute to the pathogenesis of the disease; however, with
regard to the modeling of spontaneous HCC arising from a chronic inflammatory environment, there
are considerable challenges that need to be overcome. Moreover, as it is becoming increasingly clear
that there is no unique molecular pathway underlying the pathogenesis of HCC, various models are
needed to mimic the different types of liver tumorigenesis.
This review aimed to provide a blueprint to understand the pathogenesis of HCC and optimize
the preclinical models used in drug efficacy testing.
2. Non-Genetically Engineered Mouse (GEM) Models
2.1. Chemically Induced Models
Many carcinogens that induce HCC have been identified. It has been reported that both synthetic
chemicals (such as carbon tetrachloride (CCl4), diethylnitrosamine (DENA), 2-acetylaminofluorene
(AAF), N-nitrosodimethylamine, arsenic, o-aminoazotoluene, N-nitrosomorpholine (NMOR),
and 1,2-dichloroethane) and natural substances (such as xanthosine, pyrrolizidine alkaloids, and
safrole) can be liver carcinogens [7,8]. These carcinogens are administered to the animal through food,
drinking water, gas inhalation, or intraperitoneal or subcutaneous injections. Chemically induced
HCC models are sometimes combined with liver resection to induce cell proliferation, which increases
the frequency of mutations induced by the chemical. The characteristics of each carcinogenic chemical
are summarized in Table 1.
Table 1. Chemically induced models.
Diet or Chemical Mechanism ofAction Phenotype Dose & Route References
Diethylnitrosamine
(DENA)
Genotoxic
hepatocarcinogen
50–90 weeks:
100% HCC 75–100 mg/kg IP [7–9]
N-nitrosomorpholine
(NMOR) Genotoxic
12 weeks: HCC
with lung
metastasis
120 ppm
w/drinking water [10]
Choline-deficient
and ethionine
(CDE) diet
Oxidative DNA
damage, DNA
strand breaks, and
chromosomal
instability
30–35 weeks:
100% HCC Feeding [11–13]
2-Acetylaminofluorene
(2-AAF) Genotoxic
Used primarily as
promoter in
initiation/
promotion
protocols
10 mg/kg
Oral
administration
[14,15]
HCC, hepatocellular carcinoma; IP, Intraperitoneal injection.
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Hepatic cirrhosis and multifocal HCC developed 50 weeks after intraperitoneal injection of
DENA [9–11]. When using NMOR as a carcinogen, HCC and lung metastasis were observed after
approximately 12 weeks of carcinogen supply in drinking water at a concentration of 120 ppm [12].
A choline-deficient diet with a low intake of methionine over 2 weeks can lead to rapid death of liver
cells, and their combination with DENA, azaserine, or AAF treatments can accelerate the development
of liver cancer cells [8,13–17]. This model, however, has the limitation of a large variation in the
susceptibility to choline deficiency.
Metastasis can be induced by treatment with carcinogens; however, the low long-term survival
rate of the treated animals makes it difficult to assess metastasis. In 2005, Yoshino et al. established an
animal metastasis model that showed a significantly higher survival rate than previous models [18].
It was developed by treatment with DENA at a concentration of 120 ppm, followed by the supply of
water containing NMOR at a low concentration (40 or 80 ppm) for 14 weeks. The 40 ppm NMOR-treated
model is considered to be suitable to study the mechanism of metastasis. Here, HCC develops without
lung metastasis until 22 weeks and frequent lung metastasis is found after 40 weeks.
2.2. Transplantation Models
Since 1969, when it was first identified that tumor cells implanted subcutaneously into
immunodeficient mice gave rise to cancer, many types of cell lines and tissues have been implanted in
mice for cancer research [19,20]. The transplantation model provides a suitable niche for the survival
of tumor cells in vivo. Transplantation models that use human tumor sources are classified by the type
of sample (tumor cell culture or tumor tissue obtained from surgery) and the anatomical location of
transplantation (ectopic or orthotopic) [21]. The ectopic xenograft model has the advantage of allowing
easy measurement of tumor size, thus facilitating antitumor drug efficacy testing in vivo [22]. For the
exploration of immunotherapies for HCC, syngeneic models established with immunocompetent mouse
strains are preferable; such models, however, cannot recapitulate the histology, natural carcinogenesis
characteristics, or microenvironment of human HCC [23–25]. In addition, a vaccination effect may
occur due to differences in the human and mouse immune systems [26]. Humanized mouse models
established with patient-derived xenografts and human peripheral-blood mononuclear cells (PBMCs)
can recapitulate human HCC and the human immune system, although they are expensive and require
long periods of time [27].
Ma et al. isolated CD133-expressing HCC cells from human cell lines and used them for
transplantation into immunodeficient mice to test their characteristics and resistance to chemical
drugs. These CD133-expressing tumor cells survived at a higher rate than those that did not express
CD133 [28,29]. Researchers at the University Hospital Bonn injected alcohol and thioacetamide into
C3H mice to induce liver fibrosis and, then, transplanted Hepa129 cells into the liver [30], showing
that tumor growth in the fibrotic liver is faster than that in the normal liver. In addition, Kornek et al.
found that the expression levels of vascular endothelial growth factor (VEGF), vascular endothelial
growth factor receptor (VEGFR), and matrix metalloproteinase-2 (MMP-2) and MMP-9 were higher
in tumors derived from fibrotic livers. This xenograft model has been a useful tool in drug efficacy
testing in the context of liver fibrosis. The various transplantation models are summarized in Table 2.
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Table 2. Transplantation models.
Type of Sample Characteristics(Anatomical Location) Advantage Disadvantage
Ectopic tumor xenograft
model (subcutaneous
model)
Different origin from the
cultured cells
Easy monitoring of
tumorigenicity and
tumor growth
-Unable to mount an
immune response
-Unable to predict response to
antitumor agents
Orthotopic model
implanted into the
equivalent organ from
which the cancer
originated
Reproducing the histology of
human tumors, local invasion,
and ex vivo genetic
manipulation
-Unable to mount an
immune response
-Unable to replicate
early oncogenesis
Syngeneic model
(allograft mouse model)
Tumor tissues derived
from the same genetic
background as a given
mouse strain
Intact retention of the immune
system, which is beneficial for
immunotherapy studies
Differences between the mouse
and human immune systems,
need for mouse reactive agents
Patient-derived tumor
xenograft model (PDTX)
Transplantation of the
cancer patient tissue
directly into
immunocompromised
mice
-Genetic, histological, and
phenotypic similarities with
the tumor
-Predicting the response to
anticancer drugs
-Expensive
-Time-consuming
3. GEM Models
3.1. Traditional GEMModel
The best model for human cancer should resemble the pathological and molecular characteristics of
human malignancy [31]. The model should also allow the investigation of the interactions between the
tumor microenvironment (TME) and tumor cells and provide information on the molecular signaling
pathways leading to cancer [32]. Transgenic mice were first created in the 1980s and enabled the study
and characterization of molecular signaling pathways in human malignant tumors [33–35].
Transgenic models have been engineered to express oncogenes or inactivate tumor suppressor
genes; when performed in the liver, these genetic manipulations have been shown to induce HCC [31,32].
Such gene expression can be restricted to liver cells using liver-specific promoters such as the albumin
promoter. Genes that are used to develop GEM models for HCC include those related to the hepatitis
virus, cell proliferation, and apoptosis.
3.2. Viral Genes
Chronic viral hepatitis is the most common etiology of HCC and accounts for 80% of all HCC
worldwide [36]. Hepatitis B is an endemic disease in China, Southeast Asia, and Sub-Saharan Africa,
where liver cancer shows a high incidence rate. HCV is more widely distributed in the United States
and Europe than HBV or the human immunodeficiency virus (HIV) [37].
3.2.1. Hepatitis B Virus (HBV)
HBV, a circular DNA virus that has four open reading frames, is difficult to propagate in vitro
using cell culture. The HBV X protein (HBx) is commonly used to induce HCC in murine models.
In 1994, Koike et al. showed that HCC developed in transgenic mice with high HBx expression
within 13 to 24 months in 84% of cases [38]. DNA analyses of these mice revealed that persistent
HBx expression induced DNA synthesis and secondary mutations in many hepatocytes. Moreover,
HBx transgenic mice showed differences in hepatocarcinogenesis depending on the HBV genotypes.
HCC occurred after the expression of HBx from HBV genotype C in transgenic mice, whereas HBx of
other genotypes hardly induced HCC [39].
In addition to HBx, Chisari et al. developed a transgenic model overexpressing large envelope
polypeptides of HBV [40]. This model demonstrated that the expression of a single structural viral
gene is sufficient to induce malignant transformation. The hepatocyte injury due to the accumulation
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of a viral product led to HCC via an inflammatory response, regeneration, transcriptional deregulation,
and aneuploidy. This model supported the hypothesis that sustained hepatocyte injury can induce
secondary genetic events that cause unrestricted proliferation [41].
3.2.2. Hepatitis C Virus (HCV)
HCV is an RNA virus that is not integrated into the host genome but bears proteins that exert a
wide range of biological effects by interacting with many host cell factors [42]. Several models have
been developed to understand the tumorigenesis of HCC by HCV.
Experiments using cell culture systems have shown that the core protein of HCV itself can
regulate various cell functions, which may be directly associated with the development of HCV-related
HCC [43]. The HCV core protein cooperates with the Hras oncogene in rat embryo fibroblasts, inhibits
apoptosis associated with c-Myc, and represses transcription of Tp53 [44,45]. Moreover, it allows the
peroxisome proliferator-activated receptor (PPAR) to interact with various proteins leading to hepatic
carcinogenesis [46–48].
To determine the contribution of HCV structural proteins to hepatocarcinogenesis, Kamegaya et al.
developed transgenic mice expressing only the HCV core protein or both the HCV core protein and
E1/E2 proteins [49]. HCC cell proliferation was not significantly different between the two groups;
however, HCCs in HCV core-E1/E2 transgenic mice showed significantly lower cell death rates than
those in HCV core transgenic mice. In addition, tumor size in HCV core-E1/E2 transgenic mice was
larger than that in HCV core transgenic mice.
3.2.3. Woodchuck Hepatitis Virus (WHV)
WHV belongs to the hepadnavirus family. In woodchucks, it induces hepatitis and hepatocellular
carcinoma that are remarkably similar to those associated with HBV infection in humans. Ultimately,
almost all WHV infections develop into well-differentiated HCCs. HCC is generally caused by the
overexpression of the c-Myc and N-Myc genes when the WHV DNA is integrated at a specific location
of the genome [50,51].
Viral-derived HCC models are valuable for long-term testing of chemoprevention strategies and
evaluating targeted therapies for established HCCs. However, these models have severe limitations,
such as a long latency of HCC development (usually over 2 years).
3.3. Manipulation of Host Proto-Oncogenes and Tumor Suppressor Genes
To induce HCC, liver-specific promoters are employed to drive the expression of oncogenes.
Several promoters have been used for hepatic expression, such as albumin, metallothionein,
transtthyretin, and liver activator protein (LAP) [49,52–55].
Sandgren et al. developed transgenic mice that specifically expressed c-Myc in the liver using an
albumin enhancer/promoter. In this experiment, c-Myc expression resulted in mild to severe levels of
hepatic dysfunction in young mice and hepatoblastoma in old mice after 15 months [56]. Furthermore,
it was shown that c-Myc could lead to a mutation in the β-catenin gene that led to changes in β-catenin
signaling transduction, which eventually led to HCC [57].
To investigate the interaction between c-Myc and transforming growth factor alpha (TGF-α) in HCC
development, a double transgenic mouse model was developed. It expressed c-Myc through an albumin
enhancer/promoter and TGF-α through a metallothionein 1 promoter [58–61]. This model significantly
reduced the HCC onset time compared to transgenic mice expressing c-Myc or TGF-α individually.
The mouse model co-expressing c-Myc and TGF-α induced continuous hepatocyte proliferation,
followed by tumor development 2 months later [59]. Compared to lesions caused by c-Myc expression
alone at 10 weeks, the simultaneous expression of c-Myc and TGF-α significantly increased the
production of reactive oxygen species (ROS), genetic instability, and loss of heterozygosity [62].
Other double transgenic mice models expressing c-Myc plus E2F1 or c-Myc plus EGF were also
developed [61,63,64].
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β-Catenin, the key downstream effector of the Wnt signaling pathway, plays an important
role in the liver. Activation of the Wnt/β-catenin pathway in humans can occur via an activating
mutation within the β-catenin gene or the reduced expression of adenomatous polyposis coli (APC),
a negative regulator of β-catenin [57]. GEM models expressing an activated form of β-catenin or
with a liver-specific Apc knockout showed hepatomegaly or HCC with a long latency [65]. However,
the coexpression of activated β-catenin with an activated Ras led to HCC as early as 8 weeks [66].
The phosphatase and tensin homolog (PTEN) is a tumor suppressor that negatively regulates
the PI3K-Akt signaling pathway, which, in turn, regulates cell survival, proliferation, and energy
metabolism. GEM models with a Pten deletion in the liver exhibited HCC after 44 weeks [67].
The characteristics of each mouse model using proto-oncogenes or tumor suppressor genes are
summarized in Table 3.
Table 3. HCC mouse models with proto-oncogenes or tumor suppressor genes.
Proto-Oncogene Tumor SuppressorGene
Time to
Development Characteristics
c-Myc/TGF-α 15 months Increased ROS and genetic instabilityLoss of heterozygosity
β-Catenin/RAS 8 weeks Well-differentiated HCC with a compactand trabecular pattern
Ras + c-Myc 2 months Moderately differentiated HCC
Ras p53 1 months Poorly differentiated HCC
c-Myc p53 7 months Well-differentiated HCC
myr-Akt + NRasV12 3–4 weeks Mixed HCC and ICCA
myr-Akt + Spry2Y55F 3–4 months HCC with emperipolesis
NICD1 4–5 months ICCA
myr-Akt + NICD –3 weeks ICCA
ICCA, intrahepatic cholangiocarcinoma; ROS, reactive oxygen species; HCC, hepatocellular carcinoma; ICCA,
intrahepatic cholangiocarcinoma.
3.4. Inducible Gene Expression Models
Employing a liver-specific promoter allows an oncogene to be specifically expressed in cells of the
hepatic lineage from embryogenesis [32]. Considering HCC usually develops in adults via somatic
mutations, the expression of an oncogene since early embryonic development might cause embryonic
lethality or unexpected abnormal characteristics that could make the HCC model deviate from human
HCC [68]. Additionally, to investigate the so-called oncogenic addiction, one might want to inactivate
the driver oncogene in transgenic mice after establishing liver cancer. Thus, systems that exert temporal
control of target gene expression, such as the tamoxifen-regulated Cre-loxP and the tetracycline (Tet)
regulatory systems, are sometimes favored.
In the tamoxifen-regulated Cre-loxP system, the expression of a gene of interest can be induced
with tamoxifen treatment. In the absence of tamoxifen, a Cre-estrogen receptor fusion protein (Cre-ER)
remains in the cytosol. However, in response to tamoxifen introduced via an intraperitoneal injection,
Cre-ER is translocated into the nucleus and induces recombination between loxP sites, resulting in the
removal of transcriptional stop DNA elements (Figure 1A). This allows the target gene to be expressed
in the liver by a liver-specific promoter (LSP) [69–71]. Virus-mediated Cre delivery systems are
another option for temporal control of target gene expression in the liver. For example, a recombinant
adenovirus expressing the Cre gene can be used to remove a floxed target gene (Figure 1B) [72,73].
Colnot et al. created a transgenic mouse in which the tumor suppressor gene Apc was located between
two loxP sites. Intravenously injected Cre-adenovirus induced the deletion of Apc in a liver-specific
manner. After 8 months, 67% of the mice developed liver cancer and the signaling pathway of β-catenin
was strongly upregulated in the Apc-inactivated HCC [65].
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Figure 1. Liver-Specific Genetic Modification Models. (A) Cre-ER translocates into the nucleus and
induces recombination between loxP sites. (B) recombinant adenovirus removes a floxed target gene.
(C) doxycycline (Dox) suppresses the transcription of the gene of interest. (D) Dox activates rtTA by
attaching it to the promoter and promotes the transcription of the target gene.
The Tet-Off system uses the tetracycline transactivator (tTA), whereas the Tet-On system uses
the reverse tetracycline-controlled transactivator (rtTA). In the Tet-Off system, doxycycline (Dox)
suppresses the transcription of the gene of interest by preventing tTA from attaching to the promoter
(Figure 1C). Conversely, in the Tet-On system, Dox activates rtTA by attaching it to the promoter, which,
in turn, promotes the transcription of the target gene (Figure 1D). These inducible gene expression
systems have been used in c-Myc-induced liver cancer studies. Shachaf et al. developed a mouse
model in which c-Myc was regulated by the tetracycline promoter and tTA was regulated by the
liver-specific LAP promoter [55]. The mouse model expressed c-Myc in the liver but not when treated
with Dox (Tet-Off c-Myc model). Liver cancer occurred in all transgenic mice with upregulated c-Myc
after approximately 12 weeks. After 4 days of Dox treatment, liver cancer differentiated into normal
hepatocytes with apoptosis and almost all of it was eliminated within 2 weeks.
3.5. Hydrodynamics-Based Transfection and Sleeping Beauty (SB) Transposon
Recently, a simple liver-specific transgenic approach that employs the SB transposase system and
the hydrodynamics-based transfection (HT) method was developed to create a mouse model for liver
cancer (Figure 2A, Table 4). HT is a simple physical method to deliver naked DNA plasmids to liver
cells [74]. As episomal plasmids only allow the transient expression of a target gene, chromosomal
integration is required to sustain gene expression. The SB transposase mediates chromosomal
integration of transposons; thus, the gene to be expressed is placed in the plasmid between specific
repeating sequences (IRs). The transposase recognizes this position and integrates the gene into the
chromosome [75–77]. A variety of transgenic mouse models have been developed using this method,
through which the oncogenic signaling pathway is activated or the tumor suppressor pathway is
inactivated. A selection of representative models using HT is summarized in Table 4 with emphasis on
the most recent findings.
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Figure 2. Schematic illustration of the HT-based mouse model using the SB transposase system (A)
and CRISPR/Cas9 genome editing tool (B).
3.5.1. Combination of Genetic Modifications and Disease-Specific Injury
Transgenic mice expressing an activated form of the Akt proto-oncogene, which were created
using HT and the SB transposon, developed HCC after 6 months [78]. This model showed high
similarity to a transgenic mouse model in which Pten was knocked out in the liver via traditional
genetic manipulation [79].
Studies showed that transgenic mouse models overexpressing only the c-Myc proto-oncogene
develop cancer in 60% to 70% of cases [80,81]. The tumors of c-Myc-induced models display high
heterogeneity and mimic alcohol-induced HCCs, based on genomic changes. Additionally, a mouse
model expressing c-Myc in the liver and developed using HT showed liver cancer in 5 to 8 weeks,
exhibiting histological features similar to those seen in human hepatoblastoma [82]. Based on these
findings, Chung et al. used a chemical induction methodology (CCl4) combined with HT to express
c-Myc and a short hairpin RNA downregulating p53 expression (shp53) in mice [83]. The tumor
incidence with liver fibrosis was significantly higher in transgenic mice treated with CCl4 than in those
treated with vehicle.
Recent studies also showed that the overexpression of more than two oncogenes or the combination
of an activated oncogene and an inactivated tumor suppressor gene could effectively contribute in the
development of HCC models to obtain shorter latency and increased tumor induction. For instance,
activated Met and the mutation of the β-catenin gene are considered to be more frequently present in
human HCCs [84,85]. To investigate their cooperation in tumorigenesis, Tao et al. co-expressed Met
and β-catenin point mutants (S33Y or S45Y) in hepatocytes, leading to HCC development as early as 7
weeks after HT [86]. Additionally, the hepatic expression of active β-catenin and Yap1 using HT and the
SB transposon resulted in the development of hepatoblastoma (HB) in mice [87]. SPRY2, a gene with
reduced function in half of human HCCs, is known to act as a tumor suppressor in the development of
liver cancer via inhibition of the Ras signaling pathway [88]. The potential tumor suppressive role of
Spry2 in HCC was investigated by expressing a dominant negative form of Spry2 (Spry2Y55F) and an
activated β-catenin in mouse liver through hydrodynamic injection and the SB transposon system.
The HT method coupled with the SB transposon system could be useful in studies of specific
signaling roles in tumorigenesis. HCC mouse models were developed via hydrodynamic delivery of
activated Ras combined with either Tp53 downregulation or Taz activation. In these models, TGF-β
signaling played a pro-tumorigenic role during the early stages of hepatocarcinogenesis, upregulating
Snai1 [89]. In addition, Wang et al. generated intrahepatic cholangiocarcinoma (ICCA) mouse models
using this system. The overexpression of Fbxw7∆F, a dominant negative form of Fbxw7, did not cause
significant abnormalities in the mouse liver, whereas its co-expression with an activated form of Akt
resulted in ICCA [90].
Cancers 2020, 12, 14 9 of 16
3.5.2. The HT Model as a Tool for Preclinical Treatment
HCC models developed using HT and transposon methods are also very useful for evaluating the
efficacy of anticancer drugs in the liver. Zhang et al. evaluated the therapeutic potential of mTOR
inhibitor MLN0128 vs. gemcitabine/oxaliplatin using ICCA mouse models containing activated forms
of Akt (myr-Akt) and Yap (YapS127A). The study showed the antitumor potential of MLN0128 in ICCA,
suggesting that it may be superior to gemcitabine/oxaliplatin-based chemotherapy, especially in tumors
exhibiting activated Akt/mTOR signaling [91].
Liu et al. established an HCC preclinical mouse model co-expressing Akt and c-Met
proto-oncogenes. In this model, the therapeutic efficacies of sorafenib, regorafenib, the MEK inhibitor
PD901, and the pan-mTOR inhibitor MLN0128 were investigated. Treatment with PD901 or MLN0128
alone suppressed HCC growth. Simultaneous administration of both drugs showed a stronger
inhibition effect on cell cycle and tumor growth. Thus, the combination of MEK and mTOR inhibitors
may represent an effective therapeutic approach in human HCCs [92].
HT and transposon-based HCC models can also be used for testing a potential anti-HCC drug.
Chen et al. identified niclosamide ethanolamine (NEN) as a potential antitumor agent through
a bioinformatics-based search. In an HCC mouse model produced by hydrodynamic delivery
of transposons expressing activated forms of Ras and β-catenin (N90), the oral administration of
NEN significantly reduced HCC growth, with a more potent anticancer effect when combined with
sorafenib [93].
The HT method coupled with the SB transposon system is an ideal approach to study the roles
of diverse novel genes in hepatocarcinogenesis due to the simplicity and cost-effectiveness of these
techniques. The HT and SB transposon method is expected to provide insights into the biology of
hepatic tumorigenesis and allow us to test novel therapies towards precision medicine.
3.6. HT and CRISPR/Cas9
Murine models developed via HT have been widely used for genetic studies of liver cancer.
Although the transgenic methodology has considerable advantages over the traditional GEM approach,
which requires a series of time-consuming and resource-demanding steps, the transposon-based liver
cancer models also present disadvantages. First, transposons encoding oncogenes are randomly
integrated into chromosomes, affecting endogenous genes at or near the integration sites. This raises
the possibility of tumorigenesis induced by oncogenes influenced by the genomic integration location.
Second, the oncogenes in transposons are generally placed under the control of an ectopic and strong
promoter; thus, genes are expressed at an extremely high level. These shortcomings might under or
overrepresent the true tumorigenic potential of an oncogene at the endogenous locus.
To overcome these limitations, direct manipulation of endogenous genes in the liver has been
attempted using the CRISPR/Cas9 genome editing tool, which has been successfully applied in many
organisms. This genome editing technique utilizes an RNA-guided DNA endonuclease (Cas9 nuclease)
and a single guide RNA (sgRNA) that guides the Cas9 to a complementary DNA sequence where it
cleaves both DNA strands. During repair processes of double-stranded DNA breaks generated by
Cas9, insertions and deletions are created (via non-homologous end joining) or a specific nucleotide
sequence is introduced at the target site (via homology-directed repair). To induce genome editing by
the CRISPR/Cas system in the liver, plasmids encoding Cas9 and sgRNA are delivered to the liver via
the HT method (Figure 2B and Table 4).
The first successful application of the CRISPR/Cas9 system in a liver cancer model was reported
in 2014 by Tyler Jacks’ research group [94]. Using HT for the hepatic delivery of Cas9 and sgRNAs
targeting Pten and Tp53, they successfully and simultaneously induced somatic gene disruption in the
murine liver tumor suppressor genes, in a manner similar to liver tumors induced by Pten and Tp53
double knock-outs built via the traditional GEM approach. In a similar study, Liu et al. used HT and
the CRISPR/Cas9 system to inactivate Tp53 and Pten simultaneously in the livers of adult transgenic
mice that expressed the HBV large envelope polypeptide [40,95]. The hepatic gene disruption of Tp53
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and Pten in the HBV transgenic mice significantly accelerated tumorigenesis in the liver, resulting in
tumors as early as 4 months after HT.
Table 4. Mouse models of HCC generated via hydrodynamics-based transfection.
Modulation System Target Genes Tumor Type Mouse Strain Latency References
Sleeping Beauty
transposon
c-Myc HB WT FVB/N ~6 weeks [82]
Spry2Y55F + ∆N90 β-catenin HCC WT FVB/N ~6 months [88]
hMet + β-catenin (S33Y or S45Y) HCC WT FVB/N ~6 weeks [86]
c-Myc + shP53 HCC WT C57BL/6 ~7 weeks [83]
YAPS127A + ∆N90 β-catenin HB WT FVB/N ~6 weeks [91]
myr-Akt + Fbxw7∆F ICCA WT FVB/N ~6 weeks [90]
Smad7 + HRASG12V + shP53 HCC WT C57BL/6 ~5 weeks [89]
myr-Akt + YAPS127A ICCA WT FVB/N ~3 weeks [91]
myr-Akt + cMet HCC WT FVB/N ~4 weeks [92]
RasV12 + ∆N90 β-catenin HCC WT FVB/N ~4 weeks [93]
CRISPR/Cas9 sgPten + sgP53 + Cas9 CK19-positive liver tumors WT FVB/N ~3 months [95]
sgDnajb1 + sgPrkaca + Cas9 FL-HCC WT FVB/N ~14 months [96]
HB, hepatoblastoma; FL-HCC, fibrolamellar hepatocellular carcinoma.
Recently, Engelholm et al. employed HT and the CRISPR/Cas9 system to investigate the genetic
aspects of the initiation of fibrolamellar hepatocellular carcinoma (FL-HCC), a liver cancer that
predominantly affects children [96]. A 400 kb deletion on chromosome 19, which leads to gene
fusion between DnaJ heat shock protein family member B1 gene (DNAJB1) and the protein kinase
cAMP-activated catalytic subunit alpha gene (PRKACA), is repeatedly found in FL-HCC patients.
Therefore, this study attempted to investigate the role of this gene fusion event in FL-HCC using HT
and the CRISPR/Cas9 system. They designed sgRNA targeting intron 1 of murine Dnajb1 and intron 1
of murine Prkaca to induce DNA double-strand cuts in these regions. When the sgRNA and Cas9 were
delivered to wild-type mice via HT, DNA double-strand breaks were introduced at the two genetic
loci as expected; the subsequent cellular repair led to DNA end joining that created the Dnajb1–Prkaca
gene fusion, as observed in human FL-HCC. They found that mice with this gene fusion in the liver
developed tumors that have many features of human FL-HCC.
Thus, the HT and the CRISPR/Cas9 system can be used to faithfully mimic the genetic features
found in patients with liver cancer and applied to investigate the roles of genetic alterations in liver
carcinogenesis. However, CRISPR/Cas9 technology should be applied on a liver fibrosis or cirrhosis
background to correctly mirror human HCC.
4. Conclusions
A successful experimental model for HCC should reflect the biological characteristics of human
HCCs; it should also be reliable, highly reproducible, and technically simple. To date, GEM models for
liver cancer have provided invaluable information on HCC, such as the function of oncogenes and tumor
suppressor genes, the interaction between tumor and host cells, cellular responses to chemotherapeutic
agents, and the role of stem cells in tumor progression. Traditional GEM methodology requires a
series of time-consuming and resource-demanding procedures that delay the development of a variety
of liver cancer models. HT methodology, combined with either the SB transposon system or the
CRISPR/Cas9 technique, is a promising alternative to the traditional approach for generating GEM
models for liver cancer (Table 5). Further development and refinement of the HT-based GEM models
are expected to broaden our knowledge of the genetic mechanisms underlying hepatocarcinogenesis
and provide a novel therapeutic strategy targeting genes that maintain and promote liver cancer.
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Table 5. Methodologies for creating genetically engineered mouse models for liver cancer.
Method Advantages Shortcomings
Traditional transgenic and
knock-out techniques
Modification of endogenous gene
(knock-in and knock-out)
No genetic variation in an
established line
Technically challenging
Resource-demanding
Subsequent breeding and animal
maintenance required
1–2 years to establish a model
Hydrodynamics-based
transfection and Sleeping Beauty
transposon
Simple and easy procedure
A few weeks to establish a model
Random integration of transgenes
Usually uses an ectopic promoter
Genetic variation within a model (e.g.,
transgene copy, integration site)
Hydrodynamics-based
transfection and CRISPR/Cas9
Simple and easy procedure
A few weeks or months to
establish a model
Modification of endogenous genes
Possible genetic variation within a
model (e.g., off-target genome editing,
sequence variation at the target site)
Hepatocellular carcinoma, HCC; hepatoblastoma, HB; intrahepatic cholangiocarcinoma, ICCA; genetically
engineered mouse, GEM; hydrodynamics-based transfection, HT; hepatitis B virus, HBV; hepatitis C virus,
HCV; woodchuck hepatitis virus, WHV; tumor microenvironment, TME; liver activator protein, LAP; reactive
oxygen species, ROS; tetracycline, Tet; cre-estrogen receptor, Cre-ER; liver-specific promoter, LSP; doxycycline,
Dox; Sleeping Beauty, SB; single guide RNA, sgRNA; adenomatous polyposis coli, APC; hydrodynamics-based
transfection, HT; niclosamide ethanolamine, NEN.
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